Table 1.
Baseline Patient Characteristics (N = 86)
| Characteristic N (%) | No. (%) | |
|---|---|---|
| Mean age (± SD), y | 48.2 (10.1) | |
| Menopausal status | Premenopausal | 46 (53) |
| Postmenopausal | 40 (47) | |
| Race/ethnicity | White | 38 (44) |
| Asian | 6 (7) | |
| Hispanic | 26 (30) | |
| African American | 7 (8) | |
| Other | 9 (11) | |
| Tobacco use | Never | 42 (49) |
| Current | 4 (4) | |
| Past | 40 (47) | |
| Partner status | Married | 68 (79) |
| Single/divorced | 13 (15) | |
| Widowed | 5 (6) | |
| Educational level | High school or equivalent | 30 (35) |
| College or postgraduate degree | 47 (55) | |
| Other | 8 (10) | |
| Employment status | Full time | 57 (66) |
| Part time | 16 (19) | |
| Retired | 13 (15) | |
| Stage (AJCC) of disease | I | 34 (40) |
| II | 42 (49) | |
| III | 10 (11) | |
| Surgery type | Mastectomy | 39 (45) |
| Lumpectomy | 29 (34) | |
| NA (neoadjuvant chemotherapy) | 18 (21) | |
| Chemotherapy type | Doxorubicin and cyclophosphamide plus paclitaxel | 36 (42) |
| Docetaxel and cyclophosphamide | 31 (36) | |
| Carboplatin plus paclitaxel | 8 (9) | |
| Doxorubicin and cyclophosphamide | 6 (7) | |
| Docetaxel, cyclophosphamide, and trastuzumab | 5 (6) |
Abbreviations: NA, not applicable; SD, standard deviation.